

# Qatar

Population 2015

2.2 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	<0.01 (<0.01–0.011)	0.32 (0.19–0.49)
Mortality (HIV+TB only)	<0.01 (0–<0.01)	0 (0–0.02)
Incidence (includes HIV+TB)	0.76 (0.65–0.87)	34 (29–39)
Incidence (HIV+TB only)	<0.01 (0–<0.01)	0.03 (0.02–0.04)
Incidence (MDR/RR-TB)**	0.01 (0–0.024)	0.45 (0–1.1)

## Estimated TB incidence by age and sex (thousands)\*, 2015

	0-14 years	> 14 years	Total
Females	0.047 (0.039–0.055)	0.12 (0.027–0.21)	0.17 (0.066–0.27)
Males	<0.01 (<0.01–0.012)	0.58 (0.45–0.7)	0.59 (0.46–0.72)
Total	0.056 (0.043–0.07)	0.7 (0.64–0.76)	0.76 (0.65–0.87)

## TB case notifications, 2015

Total cases notified	529
Total new and relapse	529
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	0%
- % pulmonary	52%
- % bacteriologically confirmed among pulmonary	59%

## Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2015	70% (61–81)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.01 (0.01–0.02)

## TB/HIV care in new and relapse TB patients, 2015

	Number	(%)
Patients with known HIV-status who are HIV-positive	0	
- on antiretroviral therapy	0	

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			4 (0–13)
Estimated % of TB cases with MDR/RR-TB	1.3% (0.16–4.7)	15% (13–18)	
% notified tested for rifampicin resistance			
MDR/RR-TB cases tested for resistance to second-line drugs			
Laboratory-confirmed cases		MDR/RR-TB: 13, XDR-TB:	
Patients started on treatment ****		MDR/RR-TB: 13, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New cases registered in 2014		
Previously treated cases registered in 2014		
HIV-positive TB cases, all types, registered in 2014		
MDR/RR-TB cases started on second-line treatment in 2013		
XDR-TB cases started on second-line treatment in 2013		

## TB preventive treatment, 2015

% of HIV-positive people (newly enrolled in care) on preventive treatment
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

## TB financing, 2016

National TB budget (US\$ millions)
------------------------------------

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


# Tuberculosis profile

(Rate per 100 000 population per year)



— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence


— Notified (new and relapse)

— Incidence (HIV+TB only)

## Notified cases by age group and sex, 2015



## Treatment success rate (%)



— New cases

— Previously treated cases

— HIV-positive

— MDR/RR-TB

— XDR-TB